Active Ingredient(s):Roflumilast FDA Approved: * July 29, 2022 Pharm Company: *ARCUTIS Category:Lungs (Pulmonary)
Roflumilast, sold under the trade name Daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).
In June 2010, it was approved in the European Union for severe COPD assoc...
* May have multiple approval dates, manufacturers, or labelers.